---
document_datetime: 2023-09-21 18:51:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/tritanrix-hepb-epar-all-authorised-presentations_en.pdf
document_name: tritanrix-hepb-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9126485
conversion_datetime: 2025-12-20 01:06:48.334644
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| EU Number       | Invented name   | Strength   | Pharmaceutical Form      | Route of administration   | Packaging    | Content   | Package size   |
|-----------------|-----------------|------------|--------------------------|---------------------------|--------------|-----------|----------------|
| EU/1/96/014/001 | Tritanrix HepB  | -- 1       | Suspension for injection | Intramuscular use         | vial (glass) | 0.5 ml    | 1 vial         |
| EU/1/96/014/002 | Tritanrix HepB  | -- 1       | Suspension for injection | Intramuscular use         | vial (glass) | 5.0 ml    | 1 vial         |
| EU/1/96/014/003 | Tritanrix HepB  | -- 1       | Suspension for injection | Intramuscular use         | vial (glass) | 1 ml      | 1 vial         |

1

**

adsorbed on aluminium phosphate

<!-- image -->

Medicinal product no longer authorised 1/1 Invented  name Tritanrix HepB Tritanrix HepB Tritanrix HepB 1 dose (0.5 ml) contains: Diphtheria toxoid* ≥ 30 IU Tetanus toxoid* ≥ 60 IU Inactivated Bordetella pertussis strain** ≥ 4 IU Hepatitis B virus surface Antigen recombinant** (S protein)***  10 micrograms *     adsorbed on aluminium oxide hydrated Total: 0.26 milligrams Al 3+ Total: 0.37 milligrams Al 3+ *** produced on genetically-engineered yeast cells (Saccharomyces cerevisiae)